upcyte head welcome

upcyte technologies – expanded primary cells

…. have you ever been concerned that your cell based assay is not relevant enough to provide you with satisfying results?
…. have you ever been forced to reduce the number of data points simply by the limitation of appropriate assay cells?

The possibility to scale up mammalian cells economically and the loss of cell-type specific properties have long been two sides of a coin. A downside which had to be accepted when assay reproducibility and throughput were obligatory needs.
upcyte technologies has managed to split this coin and is providing a solution which combines large scale cell expansion with physiological relevance. By using the proprietary upcyte® protocol non-dividing primary cells are pushed back into proliferation without altering their most relevant tissue-specific characteristics.
upcyte technologies can generate homogenous cell batches of up to 10 billion physiologically relevant cells from cell types which are otherwise limited. upcyte technologies provides assay-ready cells from various upcyted® human healthy or diseased tissues along with optimized medium formulations to make cell-based screening even more relevant and your early ADME-Tox screen more predictive.


Washington DC (USA) on Feb 5-8, 2017

Society of Toxicology

Baltimore (USA) on March 12-16, 2017

European ISSX

Cologne (Germany) on June 26-29, 2017

Hamburg's IFB Bank sponsors uptec's new immune cell project!

Read more herepdf


Interested in the world of primary human hepatocytes?

We helped organizing two short courses at the next ISSX meeting in June in Cologne. Find more info and the detailed program here.

upcyte technologies GmbH

Osterfeldstraße 12-14
22529 Hamburg

Tel: +49 (0) 40/63730308


© 2016 by upcyte technologies GmbH // Osterfeldstraße 12-14 // 22529 Hamburg // Germany